Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-04-16

Clinical Trial Update: A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C [Phase 2]

View source ↗

Summary

Phase 2 study to evaluate the safety and efficacy of VX-135 with ribavirin in treatment-naïve chronic hepatitis C subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ribavirin (ribavirin)
  • VX-135

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Chronic Hepatitis C | Phase 2 | Status: COMPLETED